NCT Number: NCT00040638
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Arizona Cancer Center, Tucson, Arizona, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Histologic or cytologic diagnosis of non-small cell lung carcinoma
- Progressed while on or after treatment on platinum-based regimen
- Patients may not have had more than one prior cytotoxic chemotherapy regimen
- Stage IV or IIIB
- Age at least 18 years
- Adequate liver and kidney function
- Adequate bone marrow function
Exclusion criteria
- Pregnancy or lactation
- Unstable medical conditions
- Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286
- CNS metastasis unless controlled by treatment
Treatment and study plan
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Telik
Industry
Registry information
Important dates
- Study start
- 2002
- Primary completion
- 2003
- Study completion
- 2003
- First posted
- Jul 4, 2002
- Registry last updated
- Jul 25, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
NCT04544748
Adenocarcinoma, Bronchial Neoplasms
Kazan', Russia
View Trial DetailsA Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
NCT04838548
Bronchial Neoplasms, Carcinoma, Bronchogenic
Beijing, Beijing Municipality, China
View Trial DetailsStudy of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423
Bronchial Neoplasms, Carcinoma, Bronchogenic
Long Beach, California, United States
View Trial DetailsTesting of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
NCT01652469
Bronchial Neoplasms, Carcinoma, Bronchogenic
Vienna, Austria
View Trial Details